Gemina Laboratories Stock Debt To Equity
| GLABF Stock | USD 0.55 0.01 1.79% |
Gemina Laboratories fundamentals help investors to digest information that contributes to Gemina Laboratories' financial success or failures. It also enables traders to predict the movement of Gemina OTC Stock. The fundamental analysis module provides a way to measure Gemina Laboratories' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Gemina Laboratories otc stock.
Gemina |
Gemina Laboratories OTC Stock Debt To Equity Analysis
Gemina Laboratories' Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Current Gemina Laboratories Debt To Equity | 0.01 % |
Most of Gemina Laboratories' fundamental indicators, such as Debt To Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Gemina Laboratories is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
| Competition |
According to the company disclosure, Gemina Laboratories has a Debt To Equity of 0.006%. This is 99.99% lower than that of the Healthcare sector and 99.97% lower than that of the Biotechnology industry. The debt to equity for all United States stocks is 99.99% higher than that of the company.
Gemina Debt To Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Gemina Laboratories' direct or indirect competition against its Debt To Equity to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Gemina Laboratories could also be used in its relative valuation, which is a method of valuing Gemina Laboratories by comparing valuation metrics of similar companies.Gemina Laboratories is currently under evaluation in debt to equity category among its peers.
Gemina Fundamentals
| Return On Equity | -3.47 | |||
| Return On Asset | -1.48 | |||
| Operating Margin | 979.18 % | |||
| Current Valuation | 17.22 M | |||
| Shares Outstanding | 64.1 M | |||
| Shares Owned By Insiders | 56.28 % | |||
| Price To Book | 9.70 X | |||
| Price To Sales | 5,790 X | |||
| EBITDA | (4.69 M) | |||
| Net Income | (4.73 M) | |||
| Cash And Equivalents | 2.95 M | |||
| Cash Per Share | 0.05 X | |||
| Total Debt | 12.47 K | |||
| Debt To Equity | 0.01 % | |||
| Current Ratio | 2.50 X | |||
| Book Value Per Share | 0.02 X | |||
| Cash Flow From Operations | (3.87 M) | |||
| Earnings Per Share | (0.08) X | |||
| Market Capitalization | 33.65 M | |||
| Total Asset | 1.42 M | |||
| Net Asset | 1.42 M |
About Gemina Laboratories Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Gemina Laboratories's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Gemina Laboratories using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Gemina Laboratories based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Gemina OTC Stock
Gemina Laboratories financial ratios help investors to determine whether Gemina OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Gemina with respect to the benefits of owning Gemina Laboratories security.